NasdaqGM:AVDLPharmaceuticals
How Completion of REVITALYZ Enrollment and Orphan Status at Avadel Pharmaceuticals (AVDL) Has Changed Its Investment Story
Avadel Pharmaceuticals has completed patient enrollment in REVITALYZ, its Phase 3 trial testing once-at-bedtime LUMRYZ for idiopathic hypersomnia, advancing the drug beyond its existing US FDA-approved use in narcolepsy.
This milestone, paired with LUMRYZ’s Orphan Drug Designation in idiopathic hypersomnia, could meaningfully influence expectations for the drug’s long-term role in sleep medicine.
We’ll now explore how completion of REVITALYZ enrollment, and the prospect of label expansion...